New strategies in estrogen receptor-positive breast cancer.

  title={New strategies in estrogen receptor-positive breast cancer.},
  author={Stephen R. D. Johnston},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  volume={16 7},
Endocrine therapy has led to a significant improvement in outcomes for women with estrogen receptor-positive (ER+) breast cancer. Current questions in the adjuvant setting include the optimal duration of endocrine therapy, and the accurate molecular prediction of endocrine responsiveness using gene array-based assays compared with ER expression itself. In advanced disease, novel selective estrogen receptor antagonists (SERM) have failed to make an impact, although the pure ER antagonist… CONTINUE READING
94 Citations
68 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 94 extracted citations


Publications referenced by this paper.
Showing 1-10 of 68 references

Effect of anastrozole and tamoxifen as Clin Cancer Res

  • ATAC Trialists' Group
  • h. r 16,
  • 2010
1 Excerpt

Enhancing endocrine response with novel targeted therapies: why have the Clinical Cancer Research h. r 16, 2017

  • SRD Johnston, A Leary, LA Martin, IE Smith, M. Dowsett
  • 2010

Laptainib restores hormone sensitivity in cell models of ER-positive HER2negative breast cancer with acquired endocrine resistance

  • AF Leary, L-A Martin, S Drury, M Dowsett, SRD. Johnston
  • Clin Cancer Res
  • 2010
2 Excerpts

Paradoxical action of Clin Cancer Res

  • C Osipo, C Gajdos, H Liu, B Chen, VC. Jordan
  • J Natl Cancer Inst 2003;95:1597–608
  • 2010
1 Excerpt

Similar Papers

Loading similar papers…